Explore how thalidomide derivatives enhance T-cell responses and combat exhaustion in multiple myeloma therapies for improved patient outcomes.
David S. Siegel
Advertisement
Articles by David S. Siegel
David Samuel Dicapua Siegel, MD, shared his perspectives on promising areas of research that could advance the care of patients with myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
3
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5